STOCK TITAN

Ginkgo Bioworks Holdings Inc - DNA STOCK NEWS

Welcome to our dedicated news page for Ginkgo Bioworks Holdings (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ginkgo Bioworks Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ginkgo Bioworks Holdings's position in the market.

Rhea-AI Summary
Ginkgo Bioworks Holdings, Inc. (DNA) reported $251 million in total revenue for 2023, with $139 million in Cell Engineering services revenue, representing 31% growth over 2022. The company added 78 new Cell Programs in 2023, showing 32% growth over the previous year. Ginkgo's year-end cash balance of nearly $950 million provides a strong financial runway. The company is focused on biopharma growth, global biosecurity, and strategic partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.13%
Tags
earnings
-
Rhea-AI Summary
bit.bio, a company coding human cells for novel cures, partners with Ginkgo Bioworks (NYSE: DNA) to integrate its ioCells™ portfolio of precision reprogrammed human cells into Ginkgo's platform ecosystem. This collaboration aims to provide physiologically-relevant human cell models at scale for Ginkgo's biopharma clients, enhancing disease biology insights and accelerating preclinical research and drug discovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
-
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) announced grants of restricted stock units worth $4,292,000 to Patch Bio employees and $3,530,000 to Reverie Labs employees. The units were approved as inducements for employment, vesting over time based on continued service.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
acquisition
Rhea-AI Summary
Ginkgo Bioworks (DNA) acquires key assets of Reverie Labs to enhance AI-driven drug discovery efforts. The acquisition includes infrastructure, software, and key team members to strengthen Ginkgo's AI/ML capabilities. The move aims to accelerate the development of next-generation biological foundation models and advance AI/ML-driven experimental design.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
acquisition AI
-
Rhea-AI Summary
Ginkgo Bioworks (DNA) acquires Proof Diagnostics, a life sciences company specializing in genome engineering tools for therapeutic and diagnostic applications. The acquisition aims to enhance Ginkgo's Gene Therapy Services and advance precision gene editing capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
acquisition
-
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) acquires Patch Biosciences to enhance its gene therapy, cell therapy, and RNA therapeutics services. The acquisition aims to integrate Patch's AI platform for sequence design into Ginkgo's existing platform, offering new capabilities in genetic medicine. Ginkgo's collaborations with Pfizer and Sensible Biotechnologies, along with a successful manufacturing optimization program with Biogen, highlight the company's commitment to innovation and growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
acquisition
Rhea-AI Summary
Ginkgo Bioworks (DNA) announces the creation of the Ginkgo Technology Network, a collaborative ecosystem of technology partners aimed at enhancing R&D outcomes in biological end markets. By integrating AI, genetic medicines, biologics, and manufacturing capabilities, Ginkgo plans to provide customers with comprehensive solutions. The network aims to eliminate siloing and switching costs, with plans to expand by adding new partners over time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
-
Rhea-AI Summary
Ginkgo Bioworks partners with Qatar Free Zones Authority and Doha Venture Capital to establish the Center for Unified Biosecurity Excellence (CUBE-D) in Doha, a cutting-edge hub for global pathogen monitoring and biosecurity efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.29%
Tags
none
-
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) announced CEO Jason Kelly's participation in Cowen's 44th Annual Health Care Conference. Details available on Ginkgo's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.29%
Tags
none
Rhea-AI Summary
Ginkgo Bioworks (DNA) to host a presentation and Q&A session to review business performance for Q4 and full year 2023 on February 29, 2024. Details available on investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
earnings
Ginkgo Bioworks Holdings Inc

NYSE:DNA

DNA Rankings

DNA Stock Data

2.76B
1.10B
6.86%
85.34%
11.7%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Boston

About DNA

the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline of synthetic biology technologies to design, build, and test new organisms.